Literature DB >> 21599593

Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells.

Hiroo Hasegawa1, Minori Komoda, Yasuaki Yamada, Suguru Yonezawa, Hideaki Tsutsumida, Kazuhiro Nagai, Sunao Atogami, Kazuto Tsuruda, Akemi Osaka, Daisuke Sasaki, Katsunori Yanagihara, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Yasushi Miyazaki, Shimeru Kamihira.   

Abstract

Aberrant overexpression of membrane-associated mucin (MUC1) is implicated in the pathogenesis of cancer, particularly of adenocarcinomas. Adult T-cell leukemia/lymphoma (ATL), an aggressive neoplasm etiologically associated with human T-lymphotropic virus type-1 (HTLV-1), exhibits invasive tropism into various organs, resulting in disease progression and resistance to treatment. In the present study, we showed that MUC1 is overexpressed exclusively in cells of ATL among hematological malignancies. Furthermore, increased expression of MUC1 correlated with a poor prognosis, suggesting MUC1 to be a prognostic marker in ATL. Various functional analyses with knockdown experiments using a specific siRNA for MUC1 revealed that MUC1 is involved in cell growth, cell aggregation, and resistance to apoptosis. Although it has been shown that the anti-adhesive properties of MUC1 facilitate migration and metastasis of tumor cells, our findings indicated that MUC1 contributes to cell-cell adhesion. Mucins thus seem to play a role in the pathogenesis and/or progression of ATL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21599593     DOI: 10.3109/10428194.2011.559671

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Dina Stroopinsky; Li Yin; Jacalyn Rosenblatt; Maroof Alam; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Kristen Palmer; Maxwell D Coll; Hasan Rajabi; Athalia Pyzer; Michal Bar-Natan; Katarina Luptakova; Jon Arnason; Robin Joyce; Donald Kufe; David Avigan
Journal:  Blood       Date:  2015-06-05       Impact factor: 22.113

Review 2.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

Review 3.  The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2014-06-12

Review 4.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

5.  Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers.

Authors:  Danye Zhang; Jian Gao; Liancheng Zhu; Zhenhua Hu; Rui Hou; Shuice Liu; Mingzi Tan; Juanjuan Liu; Bei Lin
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.